1. V. A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia

Keywords: digestive tract; spondiloarthritis; microbiome

Abstract:The range of causal combinations of various types of intestinal lesions and spondyloarthritis (SpA) is extremely wide: from subclinical pathology to manifest manifestations of Crohn’s disease and ulcerative colitis. In studies of the last decade it is assumed that not only infl ammatory bowel diseases (IBD), psoriasis, but also SpA are diseases with activated innate immunity, which provides an early non-specifi c response mediated by the barrier function of the epithelium. Modern data on the cellular and molecular mechanisms of SpA pathogenesis allow rheumatologists to hypothesize the concept of a “barrier organ disease” as the preclinical stage of development of diseases belonging to the SpA group, which is based on impaired immune tolerance to autologous synanthropic microfl ora in genetically predisposed individuals.Key words: microbiome; spondyloarthritis; infl ammatory bowel disease, pathogenesis

• References total 35 ⇓ :: .
  1. Kuhn K.A, Pedraza I, Demoruelle K. Mucosal Immune Responses to Microbiota in the Development of Autoimmune Disease. Rheum Dis Clin. North Am., 2014, 40, 711–725. http://dx.doi.org/10.1016/j.rdc.2014.07.013
  2. Kriegel M. A. Self or non-self? Th e multifaceted role of the microbiota in immune-mediated diseases. Clin Immunol., 2015, 159(2), 119–21. doi: 10.1016/j.clim.2015.05.010
  3. Raza K., Gerlag D. Preclinical infl ammatory rheumatic diseases. Rheum Dis Clin North Am., 2014, 40(4):569–80. doi: 10.1016/j.rdc.2014.07.001
  4. Costello M., Robinson P., Benham H., Brown M. Th e intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol., 2015, 29(2), 202–12. doi: 10.1016/j. berh.2015.08.001
  5. Nasonov E. L., Galushko E. A., Gordeev A. V. Sovremennyj vzglyad na patogenez spondiloartritov – molekulyarnye mekhanizmy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice, 2015, 53 (3), 299–307. (In Russ.) DOI:10.14412/1995–4484–2015–299–307.
  6. Erdes Sh.F., Volnuhin E. V., Galushko E. A. Lechenie bol’nyh ankiloziruyushchim spondilitom v real’noj praktike vracha-revmatologa v Rossii. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013, 51(1), 15–20(In Russ.) DOI:10.14412/1995–4484–2013–1195.
  7. Jacques P., Van Praet L., Carron P., et al. Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am., 2012 Aug, 38(3), 569–82. doi: 10.1016/j.rdc.2012.08.012.
  8. Van Praet L., Van den Bosch F. E., Jacques P., et al. Microscopic gut infl ammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis., 2013, 72(3), 414–7.
  9. Erdes Sh.F., Folomeeva O. M., Galushko E. A., Tel’nyh M. Yu. Rezul’taty odnomomentnogo epidemiologicheskogo issledovaniya po opredeleniyu potrebnosti v genno-inzhenernyh biologicheskih preparatah dlya terapii bol’nyh revmatoidnym artritom v real’noj klinicheskoj praktike (IRAKL). Soobshchenie 1. Demografi cheskaya, social’naya i kliniko-immunologicheskaya harakteristika rossijskih bol’nyh revmatoidnym artritom. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice, 2009, 6, 4–13. (In Russ.)
  10. Goldblatt F., O’Neill S. G. Clinical aspects of autoimmune rheumatic diseases. Lancet, 2013, 382, 797–808. doi: 10.1016/ S0140–6736(13)61499–3
  11. Goldblatt F., O’Neill S. G. Clinical aspects of autoimmune rheumatic diseases. Lancet, 2013, 382, 797–808. doi: 10.1016/ S0140–6736(13)61499–3
  12. Stoll M. L. Gut microbes, immunity, and spondyloarthritis. Clin Immunol., 2015, 159(2), 134–42. doi: 10.1016/j. clim.2015.05.001
  13. Ruff W.E., Kriegel M. A. Autoimmune host-microbiota interactions at barrier sites and beyond. Trends Mol Med., 2015, 21(4), 233–44. doi: 10.1016/j.molmed.2015.02.006.
  14. Schreiber S., Rosenstiel P., Albrecht M., Hampe J., Krawczak M. Genetics of Crohn disease, an archetypal infl ammatory barrier disease. Nat Rev Genet, 2005, (6), 376–388. PMID:15861209 DOI: 10.1038/nrg1607
  15. Mattozzi C.1., Richetta A. G., Cantisani C., Macaluso L., Calvieri S. Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR / CATERPILLER family genes and microbial fl ora. J Dermatol., 2012, 39(9), 752–60. doi: 10.1111/j.1346–8138.2012.01606
  16. Skroza N.1., Proietti I., Pampena R., et al. Correlations between psoriasis and infl ammatory bowel diseases. Biomed Res Int., 2013, doi: 10.1155/2013/983902.
  17. Skroza N.1., Proietti I., Pampena R., et al. Correlations between psoriasis and infl ammatory bowel diseases. Biomed Res Int., 2013, doi: 10.1155/2013/983902.
  18. Baeten D., Breban M., Lories R., et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum., 2013, 65, 12–20.
  19. Richette P, Tubach F, Breban M, et al. Psoriasis and phenotype of patients with early infl ammatory back pain. Ann Rheum Dis., 2013, 72, 566–71.
  20. Nasonov E. L., Gordeev A. V., Galushko E. A. Revmaticheskie zabolevaniya i mul’timorbidnost’. Terapevticheskij arhiv= Th erapeutic archive. 2015, 87(5), 4–9. (In Russ.)
  21. Galushko E. A., Gordeev A. V. Koncepciya «bolezni bar’ernogo organa» v patogeneze spondiloartritov. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice., 2016, 54(2), 199–205. (In Russ.) https:// doi.org/10.14412/1995–4484–2016–199–205.
  22. Costello M-E, Ciccia F, Willner D, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol., 2015, 67(3), 686–91.
  23. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in infl ammatory bowel disease. Arthritis Rheumatol., 2015, 67(1), 128–39.
  24. Huttenhower C., A. D. Kostic, R. J. Xavier, Infl ammatory bowel disease as a model for translating the microbiome, Immunity, 2014, 40, 843–854.
  25. Costello M.E, Ciccia F, Willner D, et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol., 2014 Nov, 21. doi: 10.1002/art.38967
  26. Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsielladthe evidence. Clin Rheumatol., 2007, 26(6), 858–64.
  27. Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsielladthe evidence. Clin Rheumatol., 2007, 26(6), 858–64.
  28. Cho J.H., Gregersen P. K. Genomics and the multifactorial nature of human autoimmune disease. New Engl J Med., 2011, 365, 1612–23. doi: 10.1056/NEJMra1100030
  29. Castelino M., Eyre S., Upton M., et al. Th e bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities off ered by recent technological advances Rheumatology (Oxford), 2014, 53, 777–784.
  30. Belkaid Y., Hand T. W. Role of the microbiota in immunity and infl ammation. Cell, 2014, 157, 121–141.
  31. Fukata M, Vamadevan AS, and Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in infl ammatory disorders. Semin Immunol 2009; 21: 242 http://dx.doi. org/10.1016/j.smim.2009.06.005
  32. Schaeverbeke T, Truchetet M. E., Richez C. Gut metagenome and spondyloarthritis. Joint Bone Spine., 2013 Jul, 80(4), 349–52. doi: 10.1016/j.jbspin.2013.02.005.
  33. Faustini F.1., Zoli A, Ferraccioli G. F. Immunologic and genetic links between spondylarthropathies and infl ammatory bowel diseases. Eur Rev Med Pharmacol Sci., 2009, Suppl 1, 1–9.
  34. Ciccia F, Accardo-Palumbo A, Rizzo A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut infl ammation. Ann Rheum Dis 2013, 73(8), 1566–74.
  35. Ciccia F, Bombardieri, Rizzo A, et al. Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal infl ammation. Rheumatology, 2010, 49, 2076–2083 doi:10.1093

Full text is published :
Galushko E. A., Gordeev A. V. Gut microbiome and spondyloarthritis. Experimental and Clinical Gastroenterology. 2019;162(2): 120–124. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-120-124
Read & Download full text